Replay available

Johnson & Johnson (JNJ) Q1 2026 Earnings Call

Johnson & Johnson (NYSE: JNJ) Q1 2026 earnings conference call, held 2026-04-14. Replay captured from the company's public earnings webcast.

Tue, April 14, 2026 at 8:30 AMendedReplay
Johnson & Johnson (JNJ) Q1 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Darren Snellgrove

Vice President of Investor Relations

Joaquin Duarte

Chairman and Chief Executive Officer

Joe Walk

Chief Financial Officer

Terrence Flynn

Analyst, Morgan Stanley

Jennifer Talbot

Executive Vice President, Worldwide Chairman, Innovative Medicine

John Reed

Executive Vice President, Innovative Medicine Research and Development

Larry Beagleson

Analyst, Wells Fargo

Tim Schmid

Executive Vice President, Worldwide Chairman, MedTech

Asad Haider

Analyst, Goldman Sachs

Chris Schott

Analyst, J.P. Morgan

Alexandria Hammond

Analyst, Wolfe Research

Joanne Wench

Analyst, Citigroup

David Reisinger

Analyst, Learning Partners

Matt Mixick

Analyst, Barclays

Shugun Singh

Analyst, RBC Capital Markets

Replay transcript excerpt

Good morning and welcome to Johnson & Johnson's first quarter 2026 earnings conference call. All participants will be in listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the call over to Johnson & Johnson. You may begin. Hello, everyone. This is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the first quarter of 2026 and our financial outlook for the fall year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events, using the information available as of the date of this recording. and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges t...

More from Johnson & Johnson